AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
16 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
18 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
19 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
ABSTRACT
Background
BTK inhibitor monotherapy yields an 80%–90% overall response rate and durable survival for CLL/SLL, but most patients only achieve partial response. Even after 7–8 years of continuous treatment, the complete response rate only increases from <10% to ~30% with rare undetectable minimal residual disease (uMRD), requiring lifelong BTK inhibitor maintenance. To convert lifelong treatment to finite-duration therapy, this trial adopted sequential FCG immunochemotherapy consolidation to deepen remission in treatment-naive CLL patients, enabling safe treatment discontinuation and sustained survival for partial responders.
Methods
This trial enrolled 18–65-year-old treatment-naive CLL patients, excluding those with TP53 deletion or mutation. The regimen consisted of 12 cycles of twice-daily 160 mg zanubrutinib monotherapy, followed by 4 cycles of FCG immunochemotherapy combined with zanubrutinib. FCG dosing: fludarabine 25 mg/m² and cyclophosphamide 250 mg/m² on days 1–3 of cycles 13–16; obinutuzumab 1000 mg on cycle 13 days 0, 7, 14 and cycles 14–16 day 0. Efficacy and peripheral/bone marrow (PB/BM) MRD were assessed post-treatment. Patients with PR or better discontinued therapy, while suboptimal responders switched to alternative regimens (NCT05287984).
Results
As of July 1, 2026, 59 patients initiated frontline zanubrutinib; 56 completed monotherapy and 45 entered ZFCG consolidation. Fourteen patients withdrew before FCG consolidation: 1 with zanubrutinib intolerance, 1 with COVID-19, 2 with post-monotherapy progression, 2 switched to venetoclax-based or other chemotherapy, and 8 opted for continuous monotherapy.
The median patient age was 59 years (range 39–65), with 66% males. CLL-IPI high-risk and very-high-risk cases accounted for 20.3% and 3.4%, respectively, and 38.3% of patients had unmutated IGHV. Cytogenetic abnormalities included ATM deletion (15.3%), RB1 deletion (22.0%), and trisomy 12 (20.3%).
Among 45 consolidation-eligible patients, 39 completed all four ZFCG cycles, 4 completed 3 cycles, 1 completed 2 cycles, and 1 completed 1 cycle. After 12-cycle zanubrutinib monotherapy, the CR rate was 11.11% (5/45), and dual PB/BM uMRD CR rate was 2.22% (1/45). After 2 ZFCG cycles, the CR rate rose to 60% (27/45) with a 55.56% dual uMRD CR rate. For 42 patients finishing 3–4 cycles, CR and dual uMRD CR rates reached 73.81% and 71.43%, respectively. All 42 evaluable patients achieved PB uMRD, and 97.62% obtained BM uMRD.
Forty-four responders discontinued treatment for surveillance. Forty patients under regular MRD monitoring maintained sustained uMRD and CR/PR, with a maximum 30-month off-treatment duration. The median follow-up was 38 months. Only one patient relapsed 12 months after treatment cessation. Two deaths occurred, caused by vulvar infection and hepatitis B complications. Median PFS and OS were unreached. The 1-year PFS and OS rates were both 100.0% (95% CI, 100.0%–100.0%), and 2-year PFS and OS rates were both 97.8% (95% CI, 85.3%–99.7%).
During zanubrutinib monotherapy, grade ≥3 hematologic toxicities included thrombocytopenia (8.5%), anemia (5.1%), neutropenia (8.5%) and lymphopenia (6.8%). Common non-hematologic TEAEs were grade 1 skin bleeding (50.8%), rash (15.3%) and myalgia (10.2%); grade ≥3 non-hematologic toxicities included fever (3.4%) and pneumonia (5.1%), with no grade 4 events. In the ZFCG phase, major hematologic toxicities included lymphopenia (95.6%), neutropenia (64.4%), thrombocytopenia (75.6%) and anemia (51.1%), with grade ≥3 events dominated by lymphopenia (82.2%), neutropenia (44.4%) and thrombocytopenia (33.3%). Grade ≥3 non-hematologic TEAEs included pulmonary infection (11.1%), bronchitis (2.2%), plus one fatal grade 5 vulvar infection. No grade 4 non-hematologic toxicities or secondary cancers were observed.
Conclusion
Sequential zanubrutinib induction plus limited-cycle ZFCG immunochemotherapy markedly improves CR and dual PB/BM uMRD rates over single-agent zanubrutinib for untreated CLL. Deep uMRD remission allows safe treatment discontinuation in responders. The regimen yields favorable long-term survival and low post-discontinuation relapse with manageable toxicity, breaking the lifelong BTK inhibitor monotherapy pattern. It serves as a promising frontline option for young and middle-aged CLL patients in resource-limited areas, with further large-cohort and long-term follow-up needed for validation.